ArticleBioinformatics (Oxford, England)2023
Binding peptide generation for MHC Class I proteins with deep reinforcement learning.
Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- PepGen: conditional generation of peptides for MHC binding.Bioinformatics (Oxford, England) · 2026Article
- Generative AI for controllable protein sequence design: A survey.npj drug discovery · 2026Review
- PMGen: from peptide-MHC structure prediction to peptide generation.Bioinformatics (Oxford, England) · 2026Article
- EPIC: multi-objective guided diffusion for epitope design in TCR-pMHC complexes.Bioinformatics (Oxford, England) · 2026Article
- Discovering Plastic-Binding Peptides with Favorable Affinity, Water Solubility, and Binding Specificity Through Deep Learning and Biophysical Modeling.bioRxiv : the preprint server for biology · 2026Article
- Multi-strategy embedded framework for neoantigen vaccine maturation.Scientific reports · 2026Article
- Causal AI for cancer immunotherapy: a narrative framework review of target trial emulation, treatment-effect learning and clinical translation.Frontiers in immunology · 2026Review
- AI-driven rational design of promiscuous and selective plastic-binding peptides.Chemical science · 2025Article
- A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class I-restricted neoantigens.Briefings in bioinformatics · 2025Article
- The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapy.Research square · 2025Article
- Advances of deep Neural Networks (DNNs) in the development of peptide drugs.Future medicinal chemistry · 2025Review
- Designing microplastic-binding peptides with a variational quantum circuit-based hybrid quantum-classical approach.Science advances · 2024Article
- Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.Vaccines · 2024Review
- Integrating Reinforcement Learning and Monte Carlo Tree Search for enhanced neoantigen vaccine design.Briefings in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
motivationMHC Class I protein plays an important role in immunotherapy by presenting immunogenic peptides to anti-tumor immune cells. The repertoires of peptides for various MHC Class I proteins are distinct, which can be reflected by their diverse binding motifs. To characterize binding motifs for MHC Class I proteins, in vitro experiments have been conducted to screen peptides with high binding affinities to hundreds of given MHC Class I proteins. However, considering tens of thousands of known MHC Class I proteins, conducting in vitro experiments for extensive MHC proteins is infeasible, and thus a more efficient and scalable way to characterize binding motifs is needed.
resultsWe presented a de novo generation framework, coined PepPPO, to characterize binding motif for any given MHC Class I proteins via generating repertoires of peptides presented by them. PepPPO leverages a reinforcement learning agent with a mutation policy to mutate random input peptides into positive presented ones. Using PepPPO, we characterized binding motifs for around 10 000 known human MHC Class I proteins with and without experimental data. These computed motifs demonstrated high similarities with those derived from experimental data. In addition, we found that the motifs could be used for the rapid screening of neoantigens at a much lower time cost than previous deep-learning methods. AVAILABILITY AND IMPLEMENTATION: The software can be found in https://github.com/minrq/pMHC. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.